PTPN7

PTPN7 (HePTP) is a hematopoietic protein tyrosine phosphatase that functions as a negative regulator of MAP kinase signaling by directly dephosphorylating ERK1/2 and p38 in T cells, platelets, and other hematopoietic lineages. HePTP binds ERK1/2 and p38 (but not JNK) through an N-terminal kinase-interaction motif (KIM), and its catalytic domain dephosphorylates ERK2 at pTyr185; substrate specificity is further tuned by a KIM-adjacent kinase-specificity sequence that is redox-sensitive, and PKA-mediated phosphorylation of Ser-23 within the KIM releases MAPK binding to permit ERK activation (PMID:10206983, PMID:12583813, PMID:14613483). HePTP assembles with PP2A into a cholesterol-sensitive ~440 kDa complex that confers dual-specificity pERK phosphatase activity, coupling tyrosine and threonine dephosphorylation of ERK1/2 (PMID:12773382). In vivo, PTPN7 knockout mice exhibit elevated platelet ERK1/2 phosphorylation, enhanced GPCR-dependent platelet aggregation, and accelerated thromboembolism, establishing a physiological role in hemostasis (PMID:31266805).

1. 1995 Medium

   Before any substrates were identified, the subcellular localization of HePTP was established as discrete cytoplasmic globular compartments, and IgE receptor stimulation was shown to induce its Ca²⁺-dependent tyrosine phosphorylation, linking it to immune receptor signaling.

   Evidence Immunofluorescence and 2D electrophoresis in RBL-2H3 mast cells with receptor aggregation and Ca²⁺ manipulation

   PMID:7545170

   Open questions at the time

   • Single cell type; no substrate or binding partner identified
   • Kinase responsible for HePTP tyrosine phosphorylation unknown
   • Functional consequence of HePTP phosphorylation not determined
2. 1998 High

   The first direct functional role was established: HePTP negatively regulates TCR signaling by dephosphorylating ERK2, and this requires its catalytic activity, answering what signaling pathway HePTP controls.

   Evidence Overexpression of wild-type and C270S catalytically dead HePTP in T cells with NFAT/AP-1 reporter assays and ERK2 activation measurements

   PMID:9624114

   Open questions at the time

   • Overexpression system only; no loss-of-function in vivo
   • Direct enzymatic dephosphorylation not yet demonstrated biochemically
3. 1999 High

   The physical basis of MAPK regulation was revealed: HePTP binds ERK1/2 and p38 (but not JNK) through its noncatalytic N-terminus, establishing the KIM as a selective docking mechanism.

   Evidence Co-immunoprecipitation and deletion mapping in T cells with kinase activity readouts

   PMID:10206983

   Open questions at the time

   • Structural details of KIM-MAPK interaction unresolved
   • Whether HePTP directly dephosphorylates p38 not biochemically demonstrated
4. 2000 High

   Substrate-trapping mutagenesis proved ERK2 is a direct enzymatic substrate dephosphorylated at the activation-loop tyrosine, resolving the question of whether HePTP acts directly on ERK2 rather than through an intermediary.

   Evidence C/S and D/A substrate-trapping mutants capturing phospho-ERK2, in vitro dephosphorylation assay, deletion mutagenesis

   PMID:10702794

   Open questions at the time

   • ERK1, p38 not confirmed as direct substrates by trapping
   • In vivo validation of substrate relationship lacking
5. 2003 High

   Three studies collectively established higher-order regulation: (1) HePTP forms a ~440 kDa cholesterol-sensitive complex with PP2A conferring dual-specificity pERK phosphatase activity; (2) a kinase-specificity sequence adjacent to the KIM controls preferential p38 vs. ERK binding in a redox-sensitive manner; (3) HePTP regulates nuclear ERK translocation and megakaryocytic differentiation.

   Evidence Biochemical complex isolation with cholesterol depletion; co-IP under varying redox conditions with domain-swap analysis; antisense/overexpression in K562 cells with nuclear fractionation

   PMID:12583813 PMID:12592337 PMID:12773382

   Open questions at the time

   • Stoichiometry and direct contacts within the HePTP-PP2A complex unresolved
   • Physiological redox changes controlling KSS specificity switching not demonstrated in vivo
   • Megakaryocytic differentiation role not confirmed in primary cells or in vivo
6. 2004 High

   PKA phosphorylation of Ser-23 in the KIM was identified as the mechanism by which cAMP signaling releases ERK2 from HePTP, with PP1 reversing this modification — answering how upstream signals toggle HePTP-MAPK association.

   Evidence Site-directed mutagenesis, in vitro kinase/phosphatase assays, PKA/PP1/PP2A inhibitors, prostaglandin E2 treatment, immunofluorescence in T cells

   PMID:14613483

   Open questions at the time

   • In vivo consequence of Ser-23 phosphorylation for TCR signaling not fully dissected
   • Whether PKA regulation operates similarly in non-T-cell hematopoietic lineages unknown
7. 2005 High

   Crystal structures of the HePTP catalytic domain revealed the classical PTP fold with the WPD loop in closed conformation, and identified ERK2-mediated phosphorylation of HePTP at Thr45 and Ser72, establishing reciprocal phosphorylation between enzyme and substrate.

   Evidence X-ray crystallography with structural superposition and phosphorylation site mapping

   PMID:16226275

   Open questions at the time

   • Functional consequence of Thr45/Ser72 phosphorylation on catalytic activity not determined
   • No structure of the full-length HePTP-ERK2 complex
8. 2006 High

   Higher-resolution structures showed the KIM forming an N-terminal aliphatic helix and enabled identification of two classes of small-molecule inhibitors, opening the catalytic mechanism to chemical interrogation.

   Evidence X-ray crystallography and high-throughput screening of 24,000 compounds with docking

   PMID:16441242

   Open questions at the time

   • Inhibitor selectivity over other PTPs not extensively characterized
   • No co-crystal structure of inhibitor-bound HePTP
9. 2010 High

   E-loop/WPD-loop coordination during catalysis was elucidated: Lys182 on the E loop enhances catalytic activity through interaction with Asp236 on the WPD loop, revealing a conserved allosteric mechanism across PTPs.

   Evidence X-ray crystallography capturing open and closed states in a single crystal, Lys182 mutagenesis with kinetic assays

   PMID:21094165

   Open questions at the time

   • Whether this E/WPD loop mechanism is functionally relevant in cellular context not tested
   • No dynamics measurements beyond crystallographic snapshots
10. 2011 High

    SAXS analysis showed the resting ERK2:HePTP complex is highly extended and dynamic while the phospho-ERK2 complex is compact and ordered, revealing activation-state-dependent conformational switching in the enzyme-substrate assembly.

    Evidence Small-angle X-ray scattering with EROS ensemble refinement

    PMID:21985012

    Open questions at the time

    • No atomic-resolution structure of the full complex
    • Whether conformational compaction is required for catalysis not tested by mutagenesis
11. 2019 High

    In vivo loss-of-function established physiological importance: PTPN7 knockout mice showed elevated platelet ERK1/2 phosphorylation, enhanced GPCR-stimulated aggregation, and accelerated thromboembolism, proving HePTP is a non-redundant negative regulator of platelet MAPK signaling.

    Evidence PTPN7 knockout mouse, platelet aggregation/secretion/TXA2 assays, phospho-ERK immunoblot, pulmonary thromboembolism model

    PMID:31266805

    Open questions at the time

    • Bleeding time and hemostatic balance not fully characterized
    • Whether T cell or other immune phenotypes exist in the KO is unexplored in this study

• Several mechanistic questions remain: the structure of the full-length HePTP–ERK2 complex at atomic resolution, the functional consequences of ERK2-mediated phosphorylation of HePTP (Thr45/Ser72), and whether the HePTP–PP2A dual-specificity complex operates in vivo are unresolved.
• No atomic-resolution structure of full-length HePTP–MAPK complex
• Functional role of reciprocal ERK2-mediated phosphorylation of HePTP undetermined
• In vivo relevance of HePTP–PP2A complex not tested in knockout models
• Immune phenotypes in PTPN7 knockout mice not characterized